Recombinant human papillomavirus type 16 E7 fusion protein vaccine
治疗用重组人乳头瘤病毒16型E7融合蛋白疫苗（上海泽润安珂生物制药）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameRecombinant human papillomavirus type 16 E7 fusion protein vaccine
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Zerun Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesShanghai Zerun Biotechnology Co Ltd
Inactive CompaniesShanghai Zerun Anke Bio-Pharmaceutical Co Ltd
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A